Based on ratings from 7 stock analysts, the PTC Therapeutics Inc stock price is expected to increase by 10.27% in 12 months. This is calculated by using the average 12-month stock price forecast for PTC Therapeutics Inc. The lowest target is $17.00 and the highest is $51.00. Please note analyst price targets are not guaranteed and could be missed completely.
PTC Therapeutics Inc has a total of 7 Wall St Analyst ratings. There are 2 buy ratings, 2 ratings, and 3 sell ratings. Since most analysts have a sell consensus rating, the expectation is that PTC Therapeutics Inc will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
paul choi Goldman Sachs | Sell | $18.0 | reiterated | Jan 26, 2024 |
brian abrahams RBC Capital | Hold | $22.0 | maintained | Jan 25, 2024 |
sami corwin William Blair | Buy | None | maintained | Jan 25, 2024 |
david lebovitz Citi | Sell | $17.0 | maintained | Jan 18, 2024 |
joseph schwartz Leerink Partners | Hold | None | reiterated | Jan 10, 2024 |
tiago fauth Wells Fargo | Buy | $37.0 | initiatedcoverage | Jan 8, 2024 |
jeffrey hung Morgan Stanley | Sell | $28.0 | downgraded | Dec 19, 2023 |
tazeen ahmad Bank of America Securities | Sell | $20.0 | maintained | Dec 18, 2023 |
robyn karnauskas Truist Financial | Hold | $25.0 | maintained | Nov 21, 2023 |
kristen kluska Cantor Fitzgerald | Buy | $51.0 | maintained | Nov 19, 2023 |
gena wang Barclays | Hold | $25.0 | maintained | Oct 27, 2023 |
chris shibutani Goldman Sachs | Sell | $20.0 | maintained | Oct 27, 2023 |
joseph thome TD Cowen | Hold | $32.0 | maintained | Oct 26, 2023 |
eric joseph J.P. Morgan | Buy | $45.0 | maintained | Oct 26, 2023 |
kelly shi Jefferies | Buy | $56.0 | maintained | Sep 18, 2023 |
danielle brill Raymond James | Sell | None | downgraded | Sep 15, 2023 |
colin bristow UBS | Hold | $47.0 | maintained | Aug 8, 2023 |
andrew galler Morgan Stanley | Hold | $50.0 | maintained | Jun 30, 2023 |
judah frommer Credit Suisse | Hold | $50.0 | maintained | May 24, 2023 |
yigal nochomovitz Citi | Buy | $63.0 | rated | May 24, 2023 |
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease; bio-e platform, such as vatiquinone and utreloxastat; metabolic platform comprising sepiapterin; gene therapy platform, including an asset targeting Friedreich ataxia; oncology platform, such as Unesbulin; and other multi-platform. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
When did it IPO
2013
Staff Count
1,402
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Matthew B. Klein F.A.C.S., M.D., M.S.
Market Cap
$1.96B
In 2023, PTCT generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that PTCT's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
$33.02
MORF-USD
$37.68
NEO-USD
$14.36
ARRY-USD
$13.17
MRCY-USD
$29.13
EXPI-USD
$11.06